Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Advisory committee to assess DX-88 for HAE

Executive Summary

FDA's Pulmonary-Allergy Drugs Advisory Committee will meet Feb. 4 to discuss the BLA for Dyax's hereditary angioedema treatment DX-88 (ecallantide). A positive recommendation from the panel would help DX-88 move forward as potentially the first product approved for the treatment of acute attacks of HAE. Under priority review at FDA, the BLA has an action date in late March (1"The Pink Sheet" DAILY, Sept. 24, 2008)

You may also be interested in...

Dyax Completes Rolling BLA For HAE Candidate DX-88

Company seeks priority review, which if granted could set an FDA action date in March.

ESMO: Evidence Piles Up For AZ’s Tagrisso With ADAURA CNS Data

A new analysis of the ADAURA study shows that Tagrisso’s disease-free survival benefits in early stage EGFRm NSCLC are replicated for brain metastases, a common complication with a poor prognosis. Filings and OS data await.

Small Firms Get Year Reprieve From Compliance With US FDA’s Supplement Facts Label Changes

FDA has heard from some manufacturers that additional time is needed to meet all of the requirements, “especially during the COVID-19 pandemic.” Prior to the pandemic, agency announced enforcement discretion during 2020 for compliance by firms with more than $10m in annual sales.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts